Evommune, Inc.

US$6.65As of Sun 8 Nov 2026, 12:00 UTC
NYSE:EVMNHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (52.11%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap US$241.3M
ROIC (34.17%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$7.67
15.38%
6.60%
Hold 11|12|3|9|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.16
0.17
0.18
0.18
20.22%
15.80%
18.68%
23.87%
Revenue$M
34.67
35.76
37.63
38.46
15.17%
13.62%
14.11%
15.41%
Peers (US$241.3M)
Cap (US$)
PE
240.5M
10.86x
Capital
TTM
5Y
10Y
Leveragex
1.053
(1.023)
(0.706)
EBIT/Intx
6.598
0.131
0.114
Own earn%
(76.66)
(80.79)
(79.76)
Sh yield%
16.85
33.43
33.44
Owners
Insiders/Inst%
2.73
51.73
Short interest%
4.68
SBC / revenue%
0.90
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
10–22
$1 testx
—
Incr. ROIC%
3